Latest News Phoenix Pharmaceuticals, Inc. FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Sam Spaccamonti Co Founder Owner LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 Banned: Key Facts on the Latest FDA Decision